Despite recent guidance from the National Institute for Health and Clinical Excellence (NICE) recommending the addition of omega-3s to the cocktail of therapeutic substances to be taken postmyocardial infarction (post-MI), there has been some debate about the strength of the evidence and the relative merits of prescribing the only licensed product (Omacor) and dietary modification.
History
Publication title
Prescriber
Volume
19
Issue
9
Pagination
16-18
ISSN
0959-6682
Department/School
School of Pharmacy and Pharmacology
Publisher
A & M Publishing
Place of publication
United Kingdom
Rights statement
The definitive published version is available online at: http://interscience.wiley.com